{"protocolSection":{"identificationModule":{"nctId":"NCT01513174","orgStudyIdInfo":{"id":"GECP10-03_GOAL"},"secondaryIdInfos":[{"id":"2010-024178-21","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Spanish Lung Cancer Group","class":"OTHER"},"briefTitle":"Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone","officialTitle":"Multicenter, Randomized, Phase Ib/IIb Study to Evaluate the Efficacy and Tolerability of Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone, in Patients With EGFR Mutation Positive Advanced Non-small-cell Lung Cancer","acronym":"GOAL"},"statusModule":{"statusVerifiedDate":"2024-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2011-08","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2016-07","type":"ACTUAL"},"completionDateStruct":{"date":"2016-07","type":"ACTUAL"},"studyFirstSubmitDate":"2011-12-11","studyFirstSubmitQcDate":"2012-01-16","studyFirstPostDateStruct":{"date":"2012-01-20","type":"ESTIMATED"},"resultsFirstSubmitDate":"2022-06-08","resultsFirstSubmitQcDate":"2024-01-17","resultsFirstPostDateStruct":{"date":"2024-06-28","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-01-17","lastUpdatePostDateStruct":{"date":"2024-06-28","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Spanish Lung Cancer Group","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a study of gefitinib plus olaparib gefitinib in combination with olaparib (AZD2281) versus gefitinib alone, in patients with Epidermal Growth Factor Receptor (EGFR) mutation positive advanced non-small-cell lung cancer.","detailedDescription":"GOAL is a multicenter, randomized phase IB/II study performed in two countries, Spain and Mexico. Eligible patients were 18 years or older, treatment-naïve, pathologically confirmed stage IV NSCLC, with centrally confirmed EGFR mutations and measurable disease. Patients were randomly allocated (1:1) to receive gefitinib 250 mg daily or gefitinib 250 mg daily plus olaparib 200 mg three times daily in 28-day cycles. The primary endpoint was PFS. Secondary endpoints included overall survival (OS), response rate, safety and tolerability."},"conditionsModule":{"conditions":["Non Small Cell Lung Cancer"],"keywords":["GOAL","Lung","Non small cell lung cancer","EGFR mutations"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":186,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Control Gefitinib","type":"ACTIVE_COMPARATOR","description":"Gefitinib will be administered once daily, continuously, in 28-day cycles, as a fixed dose of 250 mg/day.","interventionNames":["Drug: Gefitinib"]},{"label":"Experimental: Gefitinib in combination with olaparib","type":"EXPERIMENTAL","description":"Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase I study) twice a day, continuously, in 28-day cycles.","interventionNames":["Drug: Gefitinib","Drug: Olaparib"]}],"interventions":[{"type":"DRUG","name":"Gefitinib","description":"Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression","armGroupLabels":["Control Gefitinib","Experimental: Gefitinib in combination with olaparib"],"otherNames":["Iressa"]},{"type":"DRUG","name":"Olaparib","description":"Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles.","armGroupLabels":["Experimental: Gefitinib in combination with olaparib"],"otherNames":["Lynparza"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression-free Survival (PFS)","description":"Defined as the length of time from the date of randomization to the date of the first documented progression of disease. \"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions\"","timeFrame":"From the date of randomization until end of follow up, up to 30 months."}],"secondaryOutcomes":[{"measure":"Overall Survival","description":"Defined as the length of time from either the date of diagnosis or the start of the treatment that patients diagnosed with the disease are still alive.","timeFrame":"From the date of randomization until end of follow up, up to 30 months"},{"measure":"Best Global Response During Treatment Period","description":"To evaluate the best global response of the treatment as measured by investigator-assessed overall response rate (ORR) according to RECIST v1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR","timeFrame":"From the date of randomization until end of follow up, up to 30 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients age 18 years or more.\n2. Histologically confirmed diagnosis of non-small-cell lung carcinoma.\n3. Stage IV disease, following the Seventh Edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual (27).\n4. Tumor tissue available (according to the criterion of the specimen-processing laboratory) for EGFR mutation assessment: to be included in the study patients should present at least one EGFR mutation (exon 19 deletion or L858R with or without T790M).\n5. Evidence of measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1.\n6. ECOG score ≤ 2.\n7. Life expectancy of ≥ 3 months.\n8. For the Phase II part of the study, patients should not have received previous treatment with chemotherapy or other agents for advanced disease: chemotherapy is allowed if the initial diagnosis of the patient is limited disease and the patient has received adjuvant or neoadjuvant treatment, as long as a minimum of 6 months has passed since the end of the adjuvant and/or neo-adjuvant chemotherapy. This criterion is not mandatory to patients to be included in the Phase I part of the study (these patients are allowed to have received a prior line of treatment for advanced disease).\n9. Patients with the following hematologic values:\n\n   * Absolute Neutrophil Count (ANC) ≥1.5 x 109/L\n   * Hemoglobin (Hb) ≥ 10 g/dl\n   * Platelets ≥ 100 x 109/L\n10. Patients with the following biochemical values:\n\n    * Bilirubin ≤ 1.5 mg/dL\n    * Aspartate aminotransferase (AST) and Alanine transaminase (ALT) \\< 1.5 upper limit of normality\n    * Creatinine clearance ≥ 60 ml/min.\n11. Patients of childbearing age of either sex must use effective contraceptive methods(barrier methods plus other birth control methods) before entering the study and while participating in the study.\n12. Patients should sign an informed consent form before inclusion in the study that specifies that the clinical trial treatment entails consent for the analysis of biological samples of tumor and blood.\n13. Patients must be available for clinical follow-up.\n\nExclusion Criteria:\n\n1. Patients diagnosed of another neoplasm, with the exception of cervical carcinoma insitu, treated squamous cell carcinoma or superficial bladder tumor (Ta and TIS), or other malignant tumors that have received curative treatment within the last 5 years before inclusion in the study.\n2. Simultaneous participation in any other study involving an investigational medicinal product, or having participated in a study less than 28 days prior to the start of study treatment.\n3. Patients with HIV infection, HCV infection, coronary disease or uncontrolled arrhythmia, uncontrolled cerebrovascular disease and other clinical conditions that, in the judgment of the investigator, contraindicate the patient's participation in the study.\n4. Past medical history of interstitial lung disease (ILD), drug-induced interstitial disease, radiation pneumonitis which required steroid treatment or any evidence of clinically active interstitial lung disease.\n5. Pre-existing idiopathic pulmonary fibrosis evidenced by CT scan at baseline.\n6. Uncontrolled seizures.\n7. Patients considered requiring radiotherapy to the lung at the time of study entry or in the near future.\n8. Known or suspected brain metastases or spinal cord compression, unless treated with surgery and/or radiation and stable without steroid treatment for at least 4 weeks prior to the first dose of study medication.\n9. Patients unable to swallow orally administered medication and patients with gastrointestinal disorders likely to interfere with absorption of the study medication.\n10. Patients who are pregnant or breastfeeding. Women of childbearing potential must have a negative pregnancy test performed within 7 days before the onset of treatment(Appendix 8).\n11. Patients receiving the following classes of inhibitors of CYP3A4 (see Appendix 5 for guidelines and wash out periods):\n\n    * Azole antifungals\n    * Macrolide antibiotics\n    * Protease inhibitors\n12. Concomitant use of known CYP3A4 inducers such as phenytoin, carbamazepine, rifampicin, barbiturates, or St John's Wort.\n13. Major surgery within 2 weeks of starting study treatment; patients must have recovered from any effects of any major surgery.\n14. Significant weight loss (= 10% of body weight) in the 6 weeks before inclusion in the study.\n15. Any condition that is unstable or could endanger the patient's safety and/or the patient's compliance with the study.\n16. Substance abuse or clinical, psychological or social conditions that can undermine the validity of the informed consent or protocol compliance.\n17. Patients who present any contraindication or suspected allergy to the products under investigation in the study. Tablets of gefitinib contain lactose: patients with rare hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose and galactose malabsorption, will not be included in this trial.\n18. Contraindication for steroid use.\n19. Impossibility to comply with treatment due to cultural or geographic circumstances.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Maria Rosario García Campelo, MD","affiliation":"Hospital Teresa Herrera","role":"STUDY_CHAIR"}],"locations":[{"facility":"H. Germans Trias i Pujol","city":"Badalona","state":"Barcelona","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"ICO Hospitalet","city":"L'Hospitalet de Llobregat","state":"Barcelona","zip":"08908","country":"Spain","geoPoint":{"lat":41.35967,"lon":2.10028}},{"facility":"H. Teresa Herrera","city":"A Coruña","country":"Spain","geoPoint":{"lat":43.37135,"lon":-8.396}},{"facility":"H. Gen. Universitario de Alicante","city":"Alicante","country":"Spain","geoPoint":{"lat":38.34517,"lon":-0.48149}},{"facility":"H. Vall d'Hebrón","city":"Barcelona","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}}]},"referencesModule":{"references":[{"pmid":"33070053","type":"RESULT","citation":"Garcia-Campelo R, Arrieta O, Massuti B, Rodriguez-Abreu D, Granados ALO, Majem M, Vicente D, Lianes P, Bosch-Barrera J, Insa A, Domine M, Reguart N, Guirado M, Sala MA, Vazquez-Estevez S, Caro RB, Drozdowskyj A, Verdu A, Karachaliou N, Molina-Vila MA, Rosell R; Spanish Lung Cancer Group (SLCG). Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL). Lung Cancer. 2020 Dec;150:62-69. doi: 10.1016/j.lungcan.2020.09.018. Epub 2020 Oct 3."}],"seeAlsoLinks":[{"label":"Spanish Lung Cancer Group website","url":"http://www.gecp.org"}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Control Gefitinib","description":"Gefitinib will be administered once daily, continuously, in 28-day cycles, as a fixed dose of 250 mg/day.\n\nGefitinib: Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression"},{"id":"FG001","title":"Experimental: Gefitinib in Combination With Olaparib","description":"Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase I study) twice a day, continuously, in 28-day cycles.\n\nGefitinib: Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression\n\nOlaparib: Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"94"},{"groupId":"FG001","numSubjects":"92"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"90"},{"groupId":"FG001","numSubjects":"84"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"8"}]}],"dropWithdraws":[{"type":"Inclusion Error","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"7"}]},{"type":"Not receive study treatment","reasons":[{"groupId":"FG000","numSubjects":"3"},{"groupId":"FG001","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The mITT population is defined as the set of patients included in the study who received at least one dose of the study drug. There are 182 patients in the mITT population.","groups":[{"id":"BG000","title":"Control Gefitinib","description":"Gefitinib will be administered once daily, continuously, in 28-day cycles, as a fixed dose of 250 mg/day.\n\nGefitinib: Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression"},{"id":"BG001","title":"Experimental: Gefitinib in Combination With Olaparib","description":"Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase I study) twice a day, continuously, in 28-day cycles.\n\nGefitinib: Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression\n\nOlaparib: Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"91"},{"groupId":"BG001","value":"91"},{"groupId":"BG002","value":"182"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"65.97","spread":"11.29"},{"groupId":"BG001","value":"63.40","spread":"11.39"},{"groupId":"BG002","value":"65.95","spread":"11.29"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"57"},{"groupId":"BG001","value":"66"},{"groupId":"BG002","value":"123"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"59"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Spain","categories":[{"measurements":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"78"},{"groupId":"BG002","value":"159"}]}]},{"title":"Mexico","categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"23"}]}]}]},{"title":"Smoking status","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Smoker","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"14"}]}]},{"title":"Former smoker","categories":[{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"53"}]}]},{"title":"Never smoker","categories":[{"measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"55"},{"groupId":"BG002","value":"115"}]}]}]},{"title":"ECOG Performance Status Scale","description":"ECOG Performance Status Scale: It describes a patient's level of functioning in terms of their ability to care for themself, daily activity, and physical ability\n\nGRADES:\n\nECOG 0: Fully active. ECOG 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature ECOG 2: Ambulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 50% of waking hours ECOG 3: Capable of only limited selfcare; confined to bed or chair more than 50% of waking hours ECOG 4: Completely disabled ECOG 5: Dead","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"ECOG 0","categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"24"},{"groupId":"BG002","value":"49"}]}]},{"title":"ECOG 1","categories":[{"measurements":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"118"}]}]},{"title":"ECOG 2","categories":[{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"15"}]}]}]},{"title":"Bone metastasis","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"55"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"61"},{"groupId":"BG002","value":"127"}]}]}]},{"title":"CNS metastasis","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Yes","categories":[{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"21"}]}]},{"title":"No","categories":[{"measurements":[{"groupId":"BG000","value":"80"},{"groupId":"BG001","value":"81"},{"groupId":"BG002","value":"161"}]}]}]},{"title":"EGFR mutation","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"EGFR exon 18","categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}]}]},{"title":"EGFR exon 20","categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}]}]},{"title":"Exon 21 L858R","categories":[{"measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"60"}]}]},{"title":"del 19","categories":[{"measurements":[{"groupId":"BG000","value":"52"},{"groupId":"BG001","value":"57"},{"groupId":"BG002","value":"109"}]}]},{"title":"UK","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"4"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival (PFS)","description":"Defined as the length of time from the date of randomization to the date of the first documented progression of disease. \"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions\"","populationDescription":"The PFS analysis is performed on the PP population","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Month","timeFrame":"From the date of randomization until end of follow up, up to 30 months.","groups":[{"id":"OG000","title":"Control Gefitinib","description":"Gefitinib will be administered once daily, continuously, in 28-day cycles, as a fixed dose of 250 mg/day.\n\nGefitinib: Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression"},{"id":"OG001","title":"Experimental: Gefitinib in Combination With Olaparib","description":"Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase I study) twice a day, continuously, in 28-day cycles.\n\nGefitinib: Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression\n\nOlaparib: Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"84"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.9","lowerLimit":"9.3","upperLimit":"13.3"},{"groupId":"OG001","value":"10.9","lowerLimit":"8.6","upperLimit":"13.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.124","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.38","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"1.00","ciUpperLimit":"1.92","otherAnalysisDescription":"The initial hypothesis estimated that the median PFS for the gefitinib group would be 10 months, while the median PFS for the gefitinib/olaparib group would be 16 months, which implied a hazard ratio (HR) of 1.6."}]},{"type":"SECONDARY","title":"Overall Survival","description":"Defined as the length of time from either the date of diagnosis or the start of the treatment that patients diagnosed with the disease are still alive.","populationDescription":"The OS analysis is performed on the mITT population.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"Month","timeFrame":"From the date of randomization until end of follow up, up to 30 months","groups":[{"id":"OG000","title":"Control Gefitinib","description":"Gefitinib will be administered once daily, continuously, in 28-day cycles, as a fixed dose of 250 mg/day.\n\nGefitinib: Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression"},{"id":"OG001","title":"Experimental: Gefitinib in Combination With Olaparib","description":"Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase I study) twice a day, continuously, in 28-day cycles.\n\nGefitinib: Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression\n\nOlaparib: Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"91"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.1","lowerLimit":"19.1","upperLimit":"28.5"},{"groupId":"OG001","value":"23.3","lowerLimit":"16.2","upperLimit":"26.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3455","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"1.220","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.806","ciUpperLimit":"1.845"}]},{"type":"SECONDARY","title":"Best Global Response During Treatment Period","description":"To evaluate the best global response of the treatment as measured by investigator-assessed overall response rate (ORR) according to RECIST v1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"From the date of randomization until end of follow up, up to 30 months","groups":[{"id":"OG000","title":"Control Gefitinib","description":"Gefitinib will be administered once daily, continuously, in 28-day cycles, as a fixed dose of 250 mg/day.\n\nGefitinib: Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression"},{"id":"OG001","title":"Experimental: Gefitinib in Combination With Olaparib","description":"Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase I study) twice a day, continuously, in 28-day cycles.\n\nGefitinib: Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression\n\nOlaparib: Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"91"}]}],"classes":[{"title":"Complete Response","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]},{"title":"Partial Response","categories":[{"measurements":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"59"}]}]},{"title":"Stable disease","categories":[{"measurements":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"12"}]}]},{"title":"Progressive Disease","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"8"}]}]},{"title":"Not evaluable","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"11"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"37 months","description":"The severity of AE will be determined using CTCAE version 4.0.","eventGroups":[{"id":"EG000","title":"Control Gefitinib","description":"Gefitinib will be administered once daily, continuously, in 28-day cycles, as a fixed dose of 250 mg/day.\n\nGefitinib: Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression","deathsNumAffected":10,"deathsNumAtRisk":91,"seriousNumAffected":39,"seriousNumAtRisk":91,"otherNumAffected":88,"otherNumAtRisk":91},{"id":"EG001","title":"Experimental: Gefitinib in Combination With Olaparib","description":"Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase I study) twice a day, continuously, in 28-day cycles.\n\nGefitinib: Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression\n\nOlaparib: Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles.","deathsNumAffected":9,"deathsNumAtRisk":91,"seriousNumAffected":22,"seriousNumAtRisk":91,"otherNumAffected":90,"otherNumAtRisk":91}],"seriousEvents":[{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":91},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":91}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":91},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":91}]},{"term":"Dyspnea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":91},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":91}]},{"term":"Other - Respiratory, Thoracic And Mediastinal Disorders","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":91},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":91}]},{"term":"Pneumonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":91},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":91}]},{"term":"Anemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":91},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":91}]},{"term":"Bone marrow aplastic","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":91},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":91}]},{"term":"Cerebral infart subjects affected","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":91},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":91}]},{"term":"Edema Limbs","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":91},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":91}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":91},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":91}]},{"term":"Mucositis oral","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":91},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":91}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":91},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":91}]},{"term":"Gastrointestinal infection","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":91},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":91}]},{"term":"Renal insuficiency","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":91},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":91}]},{"term":"Rash acneiform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":91},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":91}]},{"term":"Pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":91},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":91}]},{"term":"Asthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":91},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":91}]}],"otherEvents":[{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":28,"numAtRisk":91},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":91}]},{"term":"GGT increase","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":18,"numAtRisk":91},{"groupId":"EG001","numEvents":15,"numAffected":15,"numAtRisk":91}]},{"term":"Alkaline Phosphatase Increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":16,"numAtRisk":91},{"groupId":"EG001","numEvents":16,"numAffected":16,"numAtRisk":91}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":20,"numAtRisk":91},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":91}]},{"term":"Lipasa increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":91},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":91}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":37,"numAffected":37,"numAtRisk":91},{"groupId":"EG001","numEvents":29,"numAffected":29,"numAtRisk":91}]},{"term":"Flu like symptoms","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":91},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":91}]},{"term":"Bronchial infection","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":91},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":91}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":91},{"groupId":"EG001","numEvents":14,"numAffected":14,"numAtRisk":91}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":50,"numAffected":50,"numAtRisk":91},{"groupId":"EG001","numEvents":46,"numAffected":46,"numAtRisk":91}]},{"term":"Fever","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":91},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":91}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":23,"numAtRisk":91},{"groupId":"EG001","numEvents":51,"numAffected":51,"numAtRisk":91}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":17,"numAffected":17,"numAtRisk":91},{"groupId":"EG001","numEvents":34,"numAffected":34,"numAtRisk":91}]},{"term":"Urinary tract infection","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":14,"numAtRisk":91},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":91}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":21,"numAtRisk":91},{"groupId":"EG001","numEvents":18,"numAffected":18,"numAtRisk":91}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":12,"numAtRisk":91},{"groupId":"EG001","numEvents":12,"numAffected":12,"numAtRisk":91}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":11,"numAffected":11,"numAtRisk":91},{"groupId":"EG001","numEvents":13,"numAffected":13,"numAtRisk":91}]},{"term":"Anorexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":25,"numAtRisk":91},{"groupId":"EG001","numEvents":40,"numAffected":40,"numAtRisk":91}]},{"term":"Paronychia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":15,"numAtRisk":91},{"groupId":"EG001","numEvents":7,"numAffected":7,"numAtRisk":91}]},{"term":"Upper respiratory tract infection","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 12.0","assessmentType":"NON_SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":10,"numAtRisk":91},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":91}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Eva Pereira","organization":"Fundación GECP","email":"gecp@gecp.org","phone":"+34 934302006"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17"},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077156","term":"Gefitinib"},{"id":"C531550","term":"olaparib"}],"ancestors":[{"id":"D011799","term":"Quinazolines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}